02853nas a2200277   4500008004100000020001400041024001700055245011100072210006900183260029700252300001600549490000700565520172100572653002902293653003702322653002602359653001402385100002002399700001502419700002102434700002002455700002302475700001402498700001802512856004502530       2009                        eng d  a0041-1337  awej, 013214400aIncreasing Utilization of Human T-Cell Lymphotropic Virus (+) Donors in Liver Transplantation: Is it Safe?0 aIncreasing Utilization of Human TCell Lymphotropic Virus Donors   a(C) 2009 Lippincott Williams & Wilkins, Inc.b(1) Department of Surgery, Division of Transplantation, University of Louisville, Louisville, KY.(2) Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, KY.c2009  a1180 - 11900 v873 aBackground. Liver transplantation is the best treatment option for endstage liver disease. The human T-cell lymphotrophic virus (HTLV) has been associated with leukemia/lymphoma and progressive neurologic disease. There has, however, been an increased utilization of HTLV (+) grafts with little data available to support or discourage their use., Methods. We performed univariate and multivariate analyses related to graft and patient survival for recipients of HTLV (+) donors and compared them with recipients of HTLV (-) donors using the United Network for Organ Sharing database. Complete analysis of recipient and donor clinical and demographic factors was performed., Results. There were 81 adult recipients of HTLV (+) donors and 29,747 HTLV (-) donor recipients. HTLV (+) donors were more likely to be older, women, and black, with a higher average donor risk index and creatinine, and were more likely to be shared nationally. Recipients of HTLV (+) organs were at slightly elevated risk of graft failure (HR=1.39, 95% CI 0.91-2.11) and death (HR=1.20, CI 0.71-2.02) relative to HTLV (-) donor recipients (P=0.12 and 0.5, respectively). The risk decreased after multivariate analysis - graft survival (HR=1.20, CI 0.79-1.83) and patient survival (HR=1.06, CI 0.63-1.79)., Conclusion. Our analysis reveals no statistically significant difference in graft or patient survival between recipients of HTLV (+) and (-) donors. Serious limitations of these data are that serologic testing for HTLV has a high false positive rate and that there was a short follow-up period. Until these issues are addressed, extreme caution should be exercised when using these organs., (C) 2009 Lippincott Williams & Wilkins, Inc.10aExtended criteria donors10aHuman T-cell lymphotrophic virus10aLiver Transplantation10aUNOS data1 aMarvin, Michael1 aBrock, Guy1 aKwarteng, Kwadwo1 aNagubandi, Ravi1 aRavindra, Kadiyala1 aEng, Mary1 aBuell, Joseph  uhttps://notifylibrary.org/reference/4092